{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:52:57Z","timestamp":1791175977808,"version":"4.1.0"},"reference-count":5,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2026.1971526","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:31:55Z","timestamp":1791174715000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["AGE-related efficacy and safety of darolutamide triplet therapy in metastatic hormone-sensitive prostate cancer: are we ready for routine clinical practice?"],"prefix":"10.3389","volume":"16","author":[{"given":"Fernando","family":"Munoz","sequence":"first","affiliation":[{"name":"Department Radiation Oncology","place":["Aosta, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fiorica","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Aulss 9 Scaligera","place":["Verona, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.10.001","article-title":"Age related efficacy and safety of Darolutamide plus androgen deprivation therapy and Docetaxel in patients with metastatic hormone sensitive prostate cancer: a subgroup analysis of the phase 3 Arasens trial","volume":"9","author":"Carles","year":"2026","journal-title":"Eur Urol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e1553","article-title":"Credibility of claims of subgroup effects in randomised controlled trials","volume":"344","author":"Sun","year":"2012","journal-title":"BMJ"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmsr077003","article-title":"Statistics in medicine\u2014Reporting of subgroup analyses in clinical trials","volume":"357","author":"Wang","year":"2007","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.54.8347","article-title":"International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.12.025","article-title":"Management of prostate cancer in older patients: Updated recommendations of a working group of the International Society of Geriatric Oncology (SIOG)","volume":"72","author":"Droz","year":"2017","journal-title":"Eur Urol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1971526\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:32:02Z","timestamp":1791174722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1971526\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":5,"alternative-id":["10.3389\/fonc.2026.1971526"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1971526","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"1971526"}}